CDKL3

Cyclin-dependent kinase-like 3

755 patent compounds predicted against CDKL3, 725 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL23548732	1.00	1/20
SCHEMBL23548122	0.88	1/20
SCHEMBL23548619	0.85	1/20
SCHEMBL23548280	0.84	1/20
SCHEMBL23548092	0.83	1/20
SCHEMBL23548369	0.83	1/20
SCHEMBL23548383	0.83	1/20
SCHEMBL23548626	0.83	1/20
SCHEMBL23548806	0.82	1/20
SCHEMBL23548228	0.81	1/20
SCHEMBL23548573	0.81	1/20
SCHEMBL23548607	0.81	1/20
SCHEMBL23548689	0.81	1/20
SCHEMBL23548366	0.80	1/20
SCHEMBL23548302	0.80	1/20
SCHEMBL23548459	0.80	1/20
SCHEMBL23548560	0.80	1/20
SCHEMBL23548691	0.80	1/20
SCHEMBL23548473	0.79	1/20
SCHEMBL23548107	0.79	1/20

Germline variants in CDKL3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDKL3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDKL3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old	PHASE3	NOT_YET_RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)	PHASE3	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
Palbociclib With Everolimus + Exemestane In BC	PHASE1/PHASE2	COMPLETED
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.	PHASE2	COMPLETED
Abemaciclib + Pembrolizumab In Glioblastoma	PHASE2	WITHDRAWN
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy	PHASE2	COMPLETED
Avelumab, Palbociclib and Axitinib in Advanced RCC	PHASE2	WITHDRAWN
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets	PHASE1	UNKNOWN
The SONImage Study	nan	ACTIVE_NOT_RECRUITING
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDKL3 binder may also engage these)

Protein	Name	Similarity
Q9JM01	—	1.000	Q9JM01 →
Q4R8T9	—	1.000	Q4R8T9 →
Q4R7T5	—	0.998	Q4R7T5 →
Q8BLF2	—	0.997	Q8BLF2 →
P83102	—	0.996	P83102 →
P32801	—	0.994	P32801 →
Q6FKC6	—	0.993	Q6FKC6 →
P23561	—	0.993	P23561 →
Q6BV06	—	0.992	Q6BV06 →
Q5A6T5	—	0.991	Q5A6T5 →
G5EED4	—	0.991	G5EED4 →
P40340	—	0.991	P40340 →
O13839	—	0.990	O13839 →
C5DX31	—	0.990	C5DX31 →
O60129	—	0.990	O60129 →
O14259	—	0.990	O14259 →
Q6BKC2	—	0.990	Q6BKC2 →
Q6FQ83	—	0.989	Q6FQ83 →
Q12310	—	0.989	Q12310 →
Q6L5D4	—	0.989	Q6L5D4 →
A6ZZF6	—	0.989	A6ZZF6 →
Q08BS4	—	0.989	Q08BS4 →
Q924X7	—	0.989	Q924X7 →
Q9C9U4	—	0.989	Q9C9U4 →
Q7PLI7	—	0.989	Q7PLI7 →
Q9V3Q6	—	0.989	Q9V3Q6 →
P08458	—	0.989	P08458 →
Q5VW22	—	0.989	Q5VW22 →
P35207	—	0.989	P35207 →
Q03656	—	0.988	Q03656 →